CClinicalTrials.gg
RecruitingNCT03304847Updated Oct 3, 2023

Arrhythmogenic Substrate in Primary Cardiomyopathies and/or Channellopathies

An interventional study of ablation in Cardiomyopathy, sponsored by IRCCS Policlinico S. Donato. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-03.

Sponsored by IRCCS Policlinico S. Donato · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study assesses the value of arrhythmogenic substrate identification and elimination by catheter ablation to prevent recurrent ventricular arrhythmias and sudden cardiac death in a series of selected patients with primary cardiomyopathy and/or channellopaties with ICD implantation.

Read the detailed description

The present study is designed as a prospective single center study. All selected patients with implanted ICD to prevent VT/VF recurrence who are referred to the Arrhythmology Department of San Donato Milanese Hospital, for the management of a primary cardiomyopathy fulfilling the inclusion criteria will be enrolled. Primary cardiomyopathies include: - dilated cardiomyopathy (DCM), - arrhythmogenic right ventricular cardiomyopathy (ARVC), - left ventricular non-compaction (LVNC), - early repolarization syndrome (ER), and - hypertrophic cardiomyopathy (HCM).Channellopaties incude - Long QT syndrome and J-wave syndrome) Patients with or without a family history of BrS, will also be included. Endo-epicardial electroanatomical 3Dmapping and RFA ablation will be systematically performed according to a standardized procedure. Patients will be monitored for at least 3 days after RF ablation. Before hospital discharge, echocardiography and 12-lead ECG will be performed. Patients will be followed-up clinically after the procedure as per normal clinical practice. Follow-up visits will be systematically scheduled at 3, 6, 12, 18 and 24 months. 12-lead ECG and ICD interrogation will be performed at each follow-up visit. Patients will be instructed to immediately contact the center in case of symptoms suggestive of ventricular arrhythmias. Documentation for intercurrent events will be requested and collected. The maximal duration of study participation for the individual patients is two years.

02

Conditions studied

  • Cardiomyopathy

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients affected by cardiomyopathies and/or channellopaties (long QT syndrome and J-wave syndrome) with and without documented family history of BrS;
  • Presence of symptoms attributable to VA and/or presenting documented arrhythmic episodes;
  • Patients with an ICD already implanted;
  • Patients referred to the centre for an electrophysiological study and indication for a potential concomitant radio-frequency catheter ablation (RFA) of ventricular tachycardia (VT) or ventricular fibrillation (VF);
  • Age ≥ 18;
  • Willingness to attend follow-up examinations;
  • Written informed consent for the participation in the trial

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breast-feeding;
  • Life expectancy \< 12 months
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Other
    Ablation

    Radio-frequency catheter ablation

    Other: ablation

Interventions

  • Otherablation

    radio-frequency applications on arrhythmogenic substrate

    Also known as: radio-frequency ablation

05

What researchers measure

Primary outcomes

  1. Freedom from ventricular fibrillation or ventricular tachycardia

    Survival from recurrent ventricular arrhythmias

    Time frame: two years

Secondary outcomes

  1. Measurements of Areas of prolonged ventricular potentials obtained by electroamatomocal maps before and after ablation

    Electrophysiological characterization of the arrhythmogenic substrate by electroanatomical maps

    Time frame: 1 day

06

Study locations

1 of 1 sites recruiting
  • IRCCS Policlinico S. Donato
    San Donato Milanese, Milano 20097, Italy
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03304847
Lead sponsor
IRCCS Policlinico S. Donato
Responsible party
Carlo Pappone (Chief of Arrhythmology Deartment, IRCCS Policlinico S. Donato) — Principal investigator
First posted
Oct 9, 2017
Start date
Jan 24, 2018
Primary completion
Oct 2, 2023 (estimated)
Completion
Dec 30, 2023 (estimated)
Last update
Oct 3, 2023

Study contacts

Carlo Pappone, MD
Contact
carlo.pappone@af-ablation.org
+39 02 52774260
Carlo Pappone, MD
principal investigator · Chief of Arrhythmology Department

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion